A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients

NCT03099876 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2017-04-07

No results posted yet for this study

Summary

This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy

Conditions

  • Helicobacter Pylori Infection

Interventions

PROCEDURE

treatment period

7 days treatment or 10 days treatment

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-12-01
Completion
2018-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03099876 on ClinicalTrials.gov